Clinical Core

临床核心

基本信息

批准号：
8381178
负责人：
Baoxi Wang
金额：
$ 15.14万
依托单位：
UNIV OF MASSACHUSETTS MED SCH WORCESTER
依托单位国家：
美国
项目类别：
财政年份：
资助国家：
美国
起止时间：
至
项目状态：
未结题

来源：
https://reporter.nih.gov/project-details/8381178
关键词：
Academy Address Aliquot Animals Antibodies Antigens Antimicrobial Resistance Bacterial Vaginosis Basic Science Biomedical Engineering Blocking Antibodies Blood Boston Cervical China Chinese People Chlamydia Chlamydia Infections Chlamydia trachomatis Clinic Clinical Clinical Research Collaborations Control Groups Data Dermatology Detection Discipline of Nursing Eligibility Determination Enrollment Epidemiology Epitopes Exposure to Faculty Female Genetic Variation Genital system Genotype Goals Gonorrhea Gram&apos s stain HIV Human Immune Immune response Immunity In Vitro Infection Infertility Institutes Irrigation Laboratories Laboratory Study Laboratory Technicians Lead Left Link Lipid A Measurement Measures Medical Medical center Methods Mycoplasma genitalium Names Natural Immunity Neisseria Neisseria gonorrhoeae Nested PCR Pap smear Paper Pelvic Inflammatory Disease Process Properdin Publishing Recruitment Activity Reporting Rice Role Scheme Science Scientist Serum Sexual Partners Sexually Transmitted Diseases Site Specimen Symptoms System Testing Time Training Training Programs Trichomonas vaginalis Urethra Urethritis Urine Vaccine Antigen Vaccines Vagina Vaginal Douching Variant Visit Woman adaptive immunity arm base complement pathway cytokine design experience genital secretion interest major outer membrane protein male man member men outreach porin prevent professor routine Bacterial stain symposium therapy development transmission process vaccine candidate

项目摘要

The Clinical Core Unit will provide support for three projects: Project 2 - Genetic variations in the innate immune response to Neisseria gononhoeae; Project 4 -The Altemative Complement Pathway (ACP) and Properdin in N. gonorrhoeae infection and Project 5 - Experimental and human protective immunity to N. gononhoeae infecfion. The core will recruit eligible subjects, collect and process serum specimens and cervico/lavage specimens from women and perfomn selected laboratory tests. The Clinical Core will: 1. Identify and enroll male subjects infected with N. gononhoeae and their female spread contacts. 2. Collect epidemiologic, clinical and laboratory data on female spread contacts at the Nanjing STD Clinic. 3. Collect, process and store gonococcal strains, blood and genital secrefions from women who are the sexpartners of a man wifii gonorrhea. 4. Perfonn PCR analysis for M. genitalium and 7. vaginalis and evaluate Gram's stains of vaginal secretions for BV (Nugent's criteria) to assess eligibility of female spread contacts to partidpate in a study of the role of naturally present vaccine antitrady (and blocking anfibody) in the acquisition of gonontiea. 5. Perform porin genotyping on gonococcal strains to validate transmission of like portypes between dually infected partners (Project 5). 6. Measure anfibody levels in blood, directed against candidate vaccine anfigens (2-1-L8 and 207 epitopes) and against the target (Rmp) of blocking antibodies in uninfected female spread contacts (Project 5). 7. Provide gonococcal strains and cervico/vaginal lavage specirr^ns from gononrhea infected female spread contacts (and uninfected contacts) to Project 2 for assessment of lipid A variations in sbains and for assessment of corresponding cytokine profiles in lavage specimens. 8. Provide cervico/vaginal lavage specimens to Project 4 to assess potential for ACP activation and the role of Properdin.

临床核心单元将为三个项目提供支持：项目2-先天的遗传变异对贡氏念珠菌的免疫反应；项目4-高度补体途径（ACP）和 N.淋病感染和项目5中的适当丁基 - 对N.的实验和人类保护性免疫。 Gononhoeae Infection。核心将招募符合条件的受试者，收集和处理血清标本，以及妇女的塞维科/灌洗标本和PerfoMN选择的实验室测试。临床核心将： 1。识别并招募感染了Gononhoeae的男性受试者及其女性传播接触。 2。收集Nanjing STD诊所中女性传播接触的流行病学，临床和实验室数据。 3。收集，加工和存储淋球菌菌株，血液和生殖器隔离，来自性别的女性一个男人WiFii Gonorrhea。 4。生殖器分枝杆菌和7。阴道并评估阴道分泌物的污渍的PREFONN PCR分析在研究角色的研究中在获得Gonontiea中，天然存在的疫苗抗抗激素（并阻塞了肌动纤维）。 5。在淋球菌菌株上执行孔蛋白基因分型，以验证类似端口的传播双重传播受感染的伙伴（项目5）。 6.针对候选疫苗生育原子（2-1-L8和207表位）的血液中的血肌水平并针对未感染的女性差异接触中阻断抗体的靶标（RMP）（项目5）。 7。提供促性腺菌感染的女性传播的淋球菌菌株和宫颈/阴道灌洗。与项目2的联系人（和未感染的联系人）评估脂质A的变化评估灌洗样本中相应的细胞因子谱。 8。提供cervico/阴道灌洗样本进行项目4，以评估ACP激活的潜力和角色适当的。